The diagnostic utility of the soluble CD25-to-ferritin ratio in lymphoma-associated hemophagocytic lymphohistiocytosis.
A simple blood test ratio helps doctors identify which patients with a rare immune condition have hidden lymphoma.
This 3-institution US retrospective cohort (n=126) validates the sCD25/ferritin ratio as a useful biomarker for identifying lymphoma-associated HLH, with AUC=0.74 and strong NPV (83.3%). The findings support using this easily obtained ratio as a risk-enrichment tool to prioritize evaluation for occult lymphoma in HLH, though tissue diagnosis remains essential.
What the study was
- Study design
- Retrospective multicenter cohort study
- Population
- Adults with HLH at 3 US academic centers (n=126; 44 with LAHS)
- Sample size
- 126
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Leukemia Research
Why it surfaced
Multicenter US validation of sCD25/ferritin ratio for LAHS; practical biomarker using routine lab values; strong NPV (83%) aids clinical decision-making; addresses a diagnostically challenging and high-mortality condition.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.